SEC Comment Letter 0000000000-23-002792 to ADC Therapeutics SA (ADCT)

ADC Therapeutics SA
Date: March 21, 2023 · CIK: 0001771910 · Accession: 0000000000-23-002792

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-270570

Date

March 21, 2023

Author

Peter Graham, Esq.

Form

UPLOAD

Company

ADC Therapeutics SA

Letter

United States securities and exchange commission logo March 21, 2023 Peter Graham, Esq. General Counsel ADC Therapeutics SA Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland Re:ADC Therapeutics SA Registration Statement on Form F-3 Filed March 15, 2023 File No. 333-270570 Dear Peter Graham: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Yasin Keshvargar, Esq.

Show Raw Text

United States securities and exchange commission logo
March 21, 2023
Peter Graham, Esq.
General Counsel
ADC Therapeutics SA
Biopôle
Route de la Corniche 3B
1066 Epalinges
Switzerland
Re:ADC Therapeutics SA
Registration Statement on Form F-3
Filed March 15, 2023
File No. 333-270570
Dear Peter Graham:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Yasin Keshvargar, Esq.

SecProbe.io